Coronavirus fears are mounting.
Cities are nearing lockdowns. Schools and businesses are shutting down. The CDC has even urged Americans not to travel for the Thanksgiving holiday.
“The CDC’s Thanksgiving warning was some of the firmest guidance yet from the government on curtailing traditional gatherings to fight the outbreak,” reports Reuters.
“Whether Americans heed the warning is another matter. The deadly comeback by the virus has been blamed in part on pandemic fatigue, or people getting tired of masks and other precautions. And surges were seen last summer after Memorial Day and July Fourth, despite blunt warnings from health authorities.”
At the same time, we may be nearing a vaccine.
In fact, with a treatment that’s reportedly 95% effective with no safety concerns, Pfizer and BioNTech are racing to get the treatment to market. “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,” Pfizer and BioNTech said, as quoted by CNN.
The two companies were set to ask for emergency use authorization late last week.
“Depending on how fast this [review] is really accomplished, we might get an authorization, or conditional approval already in 2020 which might help us start distribution of the first vaccine batches already in 2020,” said BioNTech CEO Ugur Sahin.
If successful, it would be very welcomed news.
To date, the world is up to 57.03 million cases, with 1.3 million deaths. In the U.S., we have 11.7 million cases. India is up to nine million. Brazil is nearly six million. France is up to 2.13 million. Russia is up to 2.02 million, with Spain up to 1.5 million.